Piper Jaffray upgraded Corcept Therapeutics to Overweight with a $9 price target on expectations the company's pipeline, driven by Korlym, will gain traction in 2015.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here